SYMPHONY Symphony Q4 FY26 results (Jan–Mar 2026) and concall
Symphony Limited reported a challenging Q4 and FY26, marked by a 28% consolidated revenue decline and a negative PAT of ₹141 crores, largely due to a full impairment of its Australian business. Despite these setbacks, the company maintained strong gross margins and saw positive contributions from its USA and GSK China subsidiaries. Strategic actions include ring-fencing the US business, restructuring Australian operations to a distributor-led model, and expanding product diversification, with an expectation of improved summer sales in India.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 45.9%, net profit down 702.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 259 | 182 | 368 | 229 | 155 −40% | 182 +0% | 199 −46% |
| EBITDA | 72 | 33 | 99 | 23 | 27 −62% | 31 −6% | 31 −69% |
| Net profit | 67 | -4 | 44 | 37 | 28 −58% | 34 +950% | -265 −702% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
